Abstract:Abstract Diffuse midline gliomas (DMG) are an aggressive and treatment-resistant form of brain cancer in urgent need of new and effective treatment strategies. Radiation therapy (RT) is the standard of care for DMGs, but these tumors often recur locally within the high-dose radiation field. Therefore, it is imperative to discover methods of overcoming RT resistance. DMGs are often characterized by the presence of driving mutation in the tail domain of histone H3 that converts the 27th residue from a lysine to a methionine (termed H3K27M). How the H2K27M mutation controls metabolism and RT resistance is not known. Using liquid chromatography/mass spectrometry metabolomics of irradiated and non-irradiated isogenic pairs, we found that patient-derived H3K27M-expressing cells (referred to as K27M cells going forward) possess altered metabolic profiles distinct from their K27M-KO counterparts, characterized by enrichment in metabolites associated with purine metabolism following RT treatment. Stable isotope tracing with precursors for de novo purine synthesis (15N-amide glutamine) and purine salvage (2H 2,8-hypoxanthine) showed that cells harboring the H3K27M mutation upregulate the de novo synthesis of guanylates but downregulate guanylate salvage. Consistent with these findings, pediatric high-grade glioma tumors and cell lines expressing K27M express lower levels of HPRT1/HGPRT, the rate-limiting enzyme in purine salvage. These findings suggest that K27M cells are preferentially reliant on de novo purine synthesis for guanylate production and that inhibition of this pathway might overcome RT resistance. Consistent with this hypothesis, we found that mycophenolic acid (MPA), a clinically available, blood-brain penetrant inhibitor of de novo purine synthesis, radiosensitized K27M neurospheres in vitro. Combination RT+MPA increased survival (38d post-implantation) over RT alone (31.5d post-implantation) in Rag1-KO mice bearing orthotopically implanted K27M tumors but did not cure tumors. To understand potential mechanisms of treatment resistance, we performed stable isotope tracing in irradiated K27M isogenic-paired cell lines. We found an H3K27M-specific, adaptive RT-mediated increase in guanylate salvage that was accompanied by increased HGPRT protein expression following RT. Additionally, we discovered that K27M xenograft tumors had high levels of the purine salvage substrate guanine. These findings suggest that K27M cells upregulate purine salvage to evade the effects of RT, which can confer resistance to inhibitors of de novo purine synthesis. Consistent with this hypothesis, H3K27M tumors in which HPRT1 was knocked down grew without difficulty but were profoundly sensitive to RT, which cured many tumors. These findings suggest that targeting the guanylate salvage pathway in DMG-K27M tumors may be a promising strategy to overcome treatment resistance. Citation Format: Erik R. Peterson, Peter Sajjakulnukit, Andrew Scott, Caleb Heaslip, Anthony Andren, Kari Wilder-Romans, Angelica Lin, Alexandra Obrien, Zitong Zhao, Li Zhang, Sriram Venneti, Carl Koschmann, Nada Jabado, Maria G. Castro, Daniel R. Wahl. Adaptive purine metabolism drives radiation therapy resistance in H3K27M-diffuse midline glioma [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1):Abstract nr B045.

Abstract 2872: GLUT3 promotes metabolic plasticity that drives radiation resistance in glioblastoma

Abstract 387: Ionizing radiation induces lipid metabolism-associated vulnerabilities in glioblastoma multiforme

Abstract 1666: Novel Glucose Transporter Inhibitors Decrease Glioblastoma Growth and Glucose Uptake

Abstract 570: Radiation Resistance of Orthotopic Glioblastoma Xenografts is Mediated by Increasing CD133+ Cell Fraction, Mobilizing G0 Cells into G1 Phase, and Activating Self-Renewal and Mesenchymal Genes

Radiation Induced Metabolic Alterations Associate With Tumor Aggressiveness and Poor Outcome in Glioblastoma

Glut-3 Gene Knockdown as a Potential Strategy to Overcome Glioblastoma Radioresistance

GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance

M2 isoform of pyruvate kinase rewires glucose metabolism during radiation therapy to promote an antioxidant response and glioblastoma radioresistance

Abstract 5113: Fractionated radiation therapy alters energy metabolism and induces cellular quiescence exit in patient-derived orthotopic xenograft models of high-grade glioma

Radiation therapy promotes unsaturated fatty acids to maintain survival of glioblastoma

Abstract B045: Adaptive purine metabolism drives radiation therapy resistance in H3K27M-diffuse midline glioma

Abstract 427: A molecular signature for the G6PC3/SLC37A2/SLC37A4 interactors in glioblastoma disease progression and in the acquisition of a brain cancer stem cell phenotype

Abstract 690: Investigation of BH-3 mimetics as radiosensitizing agents in glioblastoma

Abstract 2887: Impact of ionizing radiation on the energy metabolism of normal and tumor cells in the brain

Functional importance of glucose transporters and chromatin epigenetic factors in Glioblastoma Multiforme (GBM): possible therapeutics

A Role for GLUT3 in Glioblastoma Cell Invasion That is Not Recapitulated by GLUT1

Targeting Glioblastoma Stem Cells with 2-Deoxy-D-Glucose (2-DG) Potentiates Radiation-Induced Unfolded Protein Response (UPR)

Abstract 4989: Targeting IL-1β mitigates radiation induced MDSC expansion & improves survival in glioblastoma

Abstract 2406: Targeting prmt5 inhibits DNA repair and enhances the radiosensitivity of GBM cells

Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma

Abstract 3875: Glioblastoma mutational profiles drive cancer cell signaling and immune evasion